Latest / Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals
Tafamidis treatment of transthyretin mediated amyloidosis (TTR) approved by FDA
Mazen Hanna, MD, Co-Director of the Cleveland Clinic’s Amyloidosis Center talks about the FDA’s recent approval of the drug Tafamidis for the treatment of ATTR Amyloidosis (also known as Amyloid Transthyretin Amyloidosis), the research behind it, what this medication does, and what this means for patients.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.